Pharmaceuticals and Life Sciences Law in Türkiye Key Developments and Predictions - 2026
The year 2026 presents both challenges and opportunities for the Turkish life sciences sector. Ongoing economic pressures, inflation, and currency fluctuations continue to impact supply chains, prompting pharmaceutical and medical device companies to carefully evaluate market strategies. At the same time, regulatory developments are strengthening the sector’s framework, providing more clarity and predictability for stakeholders.
The Ministry of Health and the Turkish Medicines and Medical Devices Agency (“Agency”) have continued to implement measures to enhance product safety, traceability, and compliance. Recent initiatives, from digital tracking systems to evolving reimbursement and Named Patient Program policies, reflect a growing emphasis on transparency, real-world evidence, and value-based decision-making, marking important progress in selected areas, but also highlighting the need for continued regulatory and institutional efforts to extend these principles across the wider healthcare and life sciences ecosystem in Türkiye.
This report provides a forward-looking overview of key regulatory and market trends in Türkiye’s life sciences industry, highlighting developments that are shaping the sector today and may influence strategy in the years ahead.
CONTENTS
- Market Access - Alternative Reimbursement Models
- Regulatory and Judicial Trends Shaping Access to NPP Products
- Fixed Exchange Rate in Pricing of Pharmaceuticals and its Impact
- Market Availability of Products and Parallel Trade
- Interactions with Healthcare Professionals, Transfer of Values and Conditions of Payment
- Medical Devices: New Sanctions and Technical Service Governance
- Healthcare System Reforms
- Food Supplements
- Plant Protection Products: Digital Governance and Traceability
